PharmaShots | Incisive News in 3 Shots

Subscribe Now

molybdenum cofactor deficiency (MoCD) Type A

BridgeBio and Origin's Nulibry (fosdenopterin) Receives the US FDA's Approval as the First Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

BridgeBio and Origin's Nulibry (fosdenopterin) Receives the US FDA's Approval as the First Therapy to Reduce the Risk of Mortality...

March 1, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us